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A B S T R A C T
In recent years, the vascular endothelium has gained attention as a key player in the initiation and development
of pregnancy disorders.
Endothelium acts as an endocrine organ that preserves the homeostatic balance by responding to changes in
metabolic status. However, in metabolic disorders, endothelial cells adopt a dysfunctional function, losing their
normal responsiveness.
During pregnancy, several metabolic changes occur, in which endothelial function decisively participates.
Similarly, when pregnancy metabolic disorders occur, endothelial dysfunction plays a key role in pathogenesis.
This review outlines the main findings regarding endothelial dysfunction in three main metabolic patholo-
gical conditions observed during pregnancy: gestational diabetes, hypertensive disorders, and obesity and hy-
perlipidemia. Organ, histological and cellular characteristics were thoroughly described. Also, we focused in
discussing the underlying molecular mechanisms involved in the cellular signaling pathways that mediate re-
sponses in these pathological conditions.
1. Introduction
Endothelium is an extensive cell monolayer that covers the inner
wall of blood vessels in acting as an interface between blood and tissues
[1]. It is composed by endothelial cells, which are bound by specific cell
to cell adhesion proteins mediated by transmembrane proteins in-
cluding tight junctions, tight junctional adhesion molecules, adherence
junctions (Cadherins) and other molecules such as PECAM (Platelet
endothelial cell adhesion molecule-1) [1]. These adhesion molecules
promote a semipermeable sealing that allows endothelium to act as a
necessary anatomic and functional interface between blood and other
tissues [2,3].
The normal physiological functions of endothelium in relation to
blood vessels are as follows: i.- to aid the blood in transporting nu-
trients, water and oxygen to the organs and to remove waste molecules
and carbon dioxide; ii.- to induce vasocontraction and vasorelaxation to
maintain normal blood pressure, and iii.- to avoid coagulation, thus
maintaining blood in liquid phase by regulating hemostasis [2,4]. These
normal functions of the endothelium are regulated by endocrine and
nervous system mechanisms and by several metabolites that commu-
nicate its cellular signaling via cell membrane proteins and receptors
[2,3]. The external signals are transmitted into intracellular signaling,
thereby eliciting intracellular genomic and non-genomic actions.
However, when endothelial dysfunction occurs, normal blood vessel
function is altered, thereby promoting abnormal organ function [2–4].
During pregnancy, several endocrine functions must be adapted to
the exceptional conditions of pregnancy, and consequently, all other
systems will change, including the circulatory system [5,6]. However,
such adaptation generates several metabolic changes affecting directly
the function and metabolism of the endothelium [5,6]. The
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endothelium plays a key role in the pathogenesis of the pregnancy-as-
sociated metabolic disorders. It is affected by the metabolic disorders by
losing its permeability control capacity, and has also been demon-
strated that mediators of inflammation convert the endothelial cells
into activated fibroblasts [7,8].
This review shows the main findings on endothelial dysfunction in
three main metabolic pathological conditions. First, we focused on
gestational diabetes because evidence shows that endothelial dysfunc-
tion is closely related to this condition during pregnancy. Furthermore,
we reviewed hypertensive disorders associated with pregnancy, such as
preeclampsia and hypertension. Endothelial dysfunction is a common
pathogenic mechanism in the development of both preeclampsia and
hypertension during pregnancy. Finally, we studied the highly asso-
ciated syndromes of obesity and hyperlipidemia during pregnancy,
because these metabolic disorders mainly causes elevated levels of
circulating lipids in fetal-maternal micro- and macrovasculature. In all
cases, we examined organ features, pathohistological changes and cel-
lular characteristics and the underlying molecular mechanisms.
2. Gestational diabetes mellitus
2.1. Gestational diabetes mellitus overview
Gestational diabetes mellitus (GDM) is increasing worldwide and
occurs in approximately 15% of pregnancies [9]. GDM occurs with
macrosomia together with altered fetal cardiovascular and fetopla-
cental vasculature functions [10]. GMD is characterized by diabetes
diagnosed within the second or third trimester of pregnancy that was
not clearly manifested prior to gestation [11,12]. Most women experi-
ence restored glucose tolerance (to normal levels) after delivery, while
GDM is associated with long-term adverse consequences for mothers
and their progeny, including metabolic syndrome and increased risk for
type-2 diabetes mellitus (T2DM) [9]. The 10-year risk of developing
T2DM for GDM after pregnancy is ~40%; for this reason, GDM is also
termed early T2DM. In both GDM and T2DM, chronic insulin resistance
and inadequate pancreatic cell compensation play critical physio-
pathological roles [13].
In normal pregnancy, maternal circulating glucose can be delivered
to the fetus via the fetoplacental circulation but is not accompanied by
maternal insulin, which cannot cross the placental barrier [6,7]. Con-
sequently, the high maternal glucose levels in GDM provoke fetal hy-
perglycemia and reactive fetal hyperinsulinemia, which lead to en-
dothelial dysfunction within the fetal micro- and macrocirculation
(similar to the findings observed in adult T2DM patients) [6,8]. Thus,
endothelial dysfunction during pregnancy produces adverse long-term
consequences for the child by increasing its susceptibility for devel-
oping T2DM and cardiovascular diseases [6,11].
It is well accepted that diabetes, beyond its classification as a me-
tabolic disease, is also considered a vascular disease because of its effect
on the macro- and microcirculation of many vascular beds [14]. For
instance, endothelial dysfunction of the fetoplacental circulation is
detected in GDM. Due to the lack of innervation in human placental
vasculature, several metabolic mechanisms, such as production of va-
soactive molecules (e.g. nitric oxide and adenosine) may lead to an
acute and fast modulation of fetoplacental vascular tone [15].
2.2. Intercellular cell adhesion molecule-1 in GDM
GDM is associated with a pro-inflammatory state in both the ma-
ternal and fetal circulation, which is produced by increased levels of
pro-inflammatory cytokines that are involved in endothelial activation,
which is characterized by increased levels of, for instance, vascular cell
adhesion molecule-1 (VCAM-1), E-Selectin and intercellular cell adhe-
sion molecule-1 (ICAM-1) [16]. Moreover, the elevated expression of
adhesion molecules facilitates leukocyte adhesion to the endothelium,
thereby contributing further to the development of GDM-associated
endothelial dysfunction [17].
ICAM-1 vascular expression is rare under normal physiological
conditions, while pathogenic factors, such as hyperglycemia, activate
its expression in endothelial cells, and an increase in soluble (s) ICAM-1
Fig. 1. Maternal hyperglycemia provokes feto-pla-
cental endothelial dysfunction.
High maternal glucose levels increase glycemia in
the feto-placental vascular circulation. In turn, fetal
endothelial cells, such HUVECs, that have been ex-
posed to high glucose levels show a decreased ca-
pacity to transport adenosine, leading to its extra-
cellular accumulation and thereby increasing
adenosine bioavailability and binding to A2A ade-
nosine receptors (A2AR). A2AR activation results in
increased L-Arginine transport via hCAT-1 and in-
creased NO synthesis by eNOS. NO downregulates
transcriptional expression of the SLC29A1 gene, re-
sulting in a reduction in the adenosine transporter
hENT-1, thus consolidating extracellular adenosine
accumulation. Furthermore, increased circulating
glucose levels provoke a pro-inflammatory environ-
ment that triggers the expression of ICAM-1, in part
via miR-137, which increases leucocyte adhesion to
endothelial cells, in parallel with increased soluble
(s)ICAM-1 levels. Moreover, GDM endothelial cells
produce increased exosomes in amounts that can
affect (in autocrine-paracrine fashion) endothelial
cells, resulting in the spreading and maintenance of
feto-placental endothelial dysfunction. In addition,
the increase of miR-101 increases the apoptosis of
GDM endothelial cells and reduces their angiogenic
capacity. Black arrows and red dotted arrows in-
dicate induction and inhibition, respectively.
C. Echeverria, et al. BBA - Molecular Basis of Disease 1866 (2020) 165414
2
is also produced, reflecting endothelial cell activation and dysfunc-
tionality [18] (Fig. 1). In this sense, pregnant women with GDM are
characterized by higher concentrations of sICAM-1, and elevated ICAM-
1 circulating levels may serve as a predictor of T2DM in women with a
clinical history of GDM [18]. Similarly, GDM-derived human umbilical
vascular endothelial cells (HUVECs) express increased levels of both
ICAM-1 transcript and protein levels as consequence of alterations in
fetal endothelial function due to maternal GDM [19].
Conversely, GDM human fetoplacental arterial endothelial cells
(hFPAECs) are demonstrated to express reduced membrane-bounded
ICAM-1 paralleled with lower sICAM-1 in cell culture supernatants
[19]. This happens without changes in ICAM-1 mRNA transcript levels
suggesting post-translational regulation mechanisms implications [20].
In fact, elevated levels of microRNA-221 and -222 observed in hFPAECs
may cause the reduced ICAM-1 expression [20]. Although, the hFPAECs
response seems to be different to those in maternal endothelium, it is
not clear if this different response is compensatory or is part of the
pathophysiological of ICAM-1 role in endothelium. Nevertheless, fur-
ther studies are necessary to elucidate the precise impact of ICAM-1
regulation by environmental alterations in both maternal and fetal
endothelium [20].
2.3. Endothelial transport alterations in gestational diabetes mellitus:
adenosine-nitric oxide interplay
Several metabolic changes have been reported in GDM umbilical
cord and placental endothelial cells, such as increased levels of reactive
oxygen species (ROS) and reactive nitrogen species (RNS), asymmetric
(NG, NG) dimethylarginine (ADMA) and nitric oxide (NO) synthesis in
umbilical cord and placental endothelial cells [21]. Moreover, GDM-
associated fetal vascular dysfunction provokes NO synthesis, L-arginine
uptake and NO bioavailability functional dissociation in human pla-
cental endothelium [21,22].
Intriguingly, GDM provokes a reduction in the fetoplacental vas-
cular dilation response to insulin or the endogenous vasodilator nu-
cleoside adenosine; the molecular mechanisms include the altered ex-
pression of insulin receptors type A (IR-A) and type B (IR-B), adenosine
receptors (ARs), L-arginine, adenosine transport and its transporters
have been observed in macro and microvascular endothelium [23].
HUVECs are an excellent noninvasive cellular model that allows the
analysis of environmental alterations to the fetal endothelium, and
molecular abnormalities, such in those in the adenosine transport
system, have usually been studied in GDM-derived HUVECs [24].
The GDM-reduced uptake of endogenous adenosine results in ele-
vated extracellular concentrations, which in turn preferentially activate
A2A adenosine receptors (A2AR) in the fetoplacental endothelium [25].
In consequence, GDM-derived HUVECs reduce adenosine transport, and
this has been identified to occur as the result of a lower human equi-
librative nucleoside transporter (hENT1) transport capacity through a
reduced Vmax rather than an altered apparent Km, as adenosine uptake
capacity efficiency remains similar to that of healthy controls; the
finding can also be explained by reduced hENT-1 expression [25].
Moreover, in GDM-derived HUVECs, an approximately 50% reduction
in nucleoside-binding sites has been described, which can also be ex-
plained by an increase in the rate of transporter internalization from the
plasma membrane to a perinuclear location [25]. Normally, hENT-1
mediates approximately 80% of adenosine transport, while residual
hENT-2 transport occurs without apparent changes in GDM [21], thus
implying the importance of hENT-1 downregulation in GDM dysfunc-
tional endothelium.
In turn, in HUVECs from normal pregnancies, adenosine transport
via hENT-1 is reduced by insulin; however, this hormone increases
hENT1 expression and activity to normal levels in GDM-derived
HUVECs [26]. The recovery of hENT-1 expression and activity by in-
sulin may reduce A2A-adenosine receptors activation by avoiding ex-
tracellular adenosine accumulation, which can downregulate L-arginine
uptake by human cationic amino acids transporter 1 (hCAT-1) transport
[23,25].
Importantly, increased NO downregulates hENT-1/SLC29A1 gene
expression by inhibiting its promoter transcriptional activity in GDM-
derive HUVECs. Indeed, GDM-derived HUVECs present elevated en-
dothelial nitric oxide synthase (eNOS) expression and activity [21] NO-
dependent repressive transcription factor complexes that comprise hC/
element-binding protein homologous protein 10 (CHOP)-CCAAT/en-
hancer-binding protein α(C/EBPα) (hCHOP-C/EBPα) interact with a
specific SLC29A1 promoter region located at −2154 to −1810 bp from
transcriptional start site loaded the inhibition of hENT-1 in GDM [26].
This observation may nicely explain the increased adenosine extra-
cellular levels found in GDM umbilical cord blood and in HUVEC cul-
ture medium compared with normal pregnancies.
Moreover, elevated extracellular adenosine levels increase ARs ac-
tivation, resulting in elevated NO production, eNOS expression and
substrate (L-arginine) transport by increasing human cationic amino
acids transporter 1 (hCAT-1) expression, collectively known as the
ALANO (Adenosine/L-arginine/Nitric Oxide) pathway [21,23]; these
effects characterize GDM endothelial dysfunction (Fig. 1). In addition,
HUVECs from GDM exhibit a higher number of copies of mRNA for
hCAT-1, which are coded by the SLC7A1 gene, which is regulated by
the Sp1 and NF-κB transcription factors [27]. Despite the increased
expression of hCAT-1, increased L-arginine transport occurs because the
transporter operates with higher maximal velocity due to intracellular
signal pathways involved in L-arginine transport activation. For in-
stance, PKC activators and ERK1,2 and MAPK activation increase L-ar-
ginase transport, and these intracellular signal transduction mechan-
isms also appear to operate in GDM-derived HUVECs [28].
Interestingly, arteries and veins in the human placenta in GDM
pregnancies exhibit increased NO synthesis [29], and this is also ob-
served in culture GDM-derived HUVECs. Although NO production
seems to be increased in the fetoplacental vasculature, its bioavail-
ability is reduced. This can be the consequence of the higher oxidative
stress observed in GDM since NO reacts with ROS, thereby depleting
bioactive NO from the circulation [10,30].
As abovementioned, insulin inhibits the increased L-arginine trans-
port and NO production observed in GDM-derived HUVECs compared
with the same cells from normal pregnancies [31]. Insulin affects
ALANO pathways in GDM-derived endothelial cells. For instance, In-
sulin increases adenosine transport via hENT-1 activation, which de-
creases the increased adenosine extracellular levels, while also de-
creasing NO production by reducing eNOs expression and activity and
L-arginine transport [23]. Thus, insulin seems to in vitro reverse GDM-
associated ALANO alterations in human fetoplacental endothelium.
ADMA can also regulate endothelial function through the inhibition
of both nitric oxide synthase and CATs, thereby reducing NO produc-
tion. ADMA may contribute to endothelial dysfunction and generate
vascular oxidative stress, which is involved in the etiopathology of
vascular and organ diseases [32]. Although, Akturk et al. [22], reported
that peripheral blood ADMA levels are elevated in GDM, indicating
endothelial activation and consequent endothelial dysfunction, Po-
niedziałek-Czajkowska et al. [18] indicates that patients with GDM
show significantly lower ADMA levels than healthy pregnant women. It
is possible that hyperglycemia decreases ADMA levels by reducing its
synthesis or by enhancing its degradation by dimethylarginine di-
methylaminohydrolase [18,22]. This last observation is consistent with
the increased L-arginine transport and NO synthesis in vascular en-
dothelium. It is important to point out that some differences exist be-
tween these two studies: while Akturk et al. [22] study normal and
GDM groups similar in obese status, with body mass index (BMI)
29.59 kg/m2 and 28.66 kg/m2 respectively, Poniedziałek-Czajkowska
et al. [18] compared obese GDM (BMI 27.93 kg/m2) with non-obese
control group with BMI 22.34 kg/m2. Although in both studies GDM
show higher circulating C - reactive protein levels, as a marker of in-
flammatory status, higher insulin levels [22] and higher oral glucose
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tolerance test values, the differences in BMI for both GDM and control
groups in both studies may turn ADMA results not comparable.
Therefore, a study considering both normal and obese BMI values to
compare with GDM patients should be addressed to resolve the dis-
parity between ADMA studies.
2.4. Endothelial exosomes and microRNAs influence endothelial
dysfunction in GDM
Components of new molecular mechanisms, including exosomes
and microRNAs (miRs), have been demonstrated to influence the GDM
dysfunctional endothelium (Fig. 1).
2.4.1. Exosomes
Exosomes are nanovesicles (40–100 nm diameter) that are secreted
into the extracellular environment by most cell types and contain
proteins, lipids, mRNAs, miRs and noncoding RNAs, thereby re-
presenting a new type of paracrine cell-cell communication [33]. In
endothelial cells, exosomes regulate such cellular functions as migra-
tion, proliferation and angiogenesis [34]. Recently, increased levels of
circulating exosomes in maternal plasma of GDM have been described
[35]. Interestingly, both placental and maternal GDM exosomes are
increased in maternal plasma. Furthermore, HUVECs treatment with
GDM-isolated exosomes increased the production of pro-inflammatory
cytokines, such as GM-CSF, IL-4, IL-6, IL-8, IFN-γ, and TNF-α [35].
Moreover, GDM-derived HUVECs exosomes increased hCAT-1 ex-
pression and L-arginine endothelial transport and NO synthesis in
normal pregnancy-derived HUVECs [36]. These results indicate the
potential contribution of GDM exosomes as autocrine or paracrine
signals to the induction and maintenance of feto-placental endothelial
dysfunction [34].
2.4.2. MicroRNAs
MiRs are short and stable noncoding RNAS that finely tune gene
expression and have been implicated in pathological conditions, in-
cluding T2DM and diabetic-associated vascular dysfunction [37]. Dys-
regulation of miRs has been described in GDM, and these biomolecules
may represent potential blood biomarkers for the diagnosis and mon-
itoring of GDM evolution in pregnant women and the fetus [38]. As
mentioned above, ICAM-1 is susceptible to regulation by miRs. miR-221
and -222, the expression of which is upregulated in human fetopla-
cental endothelial cells obtained from GDM patients, and these miRs
contribute specifically to ICAM-1 downregulation since VCAM-1 and E-
selectin are not-modified in feto-placental endothelial cells [20]. MiR-
137 has been postulated as a GDM-predictive marker for glucose-in-
duced endothelial cell dysfunction. MiR-137 is increased in the plasma
of GDM women and in high-glucose (HG)-exposed HUVECs and en-
hances monocyte adhesion to HUVECs monolayers, accompanied by
increased ICAM-1, VCAM-1, and E-selectin expression. In addition, the
angiogenic potential of HUVECs is highly reduced by miR-137. These
observations implicate miR-137 in the development of GDM, and the
authors postulated that its peripheral blood levels in pregnancy can be
useful for monitoring GDM severity [39]. Finally, GDM-derived HU-
VECs express elevated soluble miR-101 levels, and these miRs con-
tribute to the increased apoptotic endothelial rate and reduced func-
tional angiogenic capacities. These effects are partly mediated by the
miR-101 inhibition of histone methyltransferase enhancer of zester
homolog-2 expression (EZH2) in GDM-derived HUVECs, while ectopic
EZH2 expression rescues cells from reduced migratory capacities and
increased apoptotic activity. Thus, miR-101, in part by inhibiting EZH2
expression, may influence the development of endothelial dysfunction
in the fetoplacental vascular system [24]. Although, miRs have been
reported as part of exosomes also, it has not been studied yet whether
exosomes-associated miRs may influence GDM maternal and fetal vas-
culature. Nevertheless, accumulating evidence supports the notion that
epigenetic alterations confer molecular memory relating to gene
expression in cells exposed to a diabetic milieu in vivo, which can
predispose GDM pregnant women and their offspring to develop T2DM
and metabolic disorders [40].
In conclusion, GDM, as a condition of carbohydrate intolerance, is
associated with adverse maternal and offspring health outcomes and
produces an inflammatory state that impacts both the macro- and mi-
crocirculation. Thus, GDM impairs vascular structure and function.
Maternal hyperglycemia increases fetal circulating glucose levels, trig-
gering the development of fetoplacental endothelium alterations, which
are characterized by the inflammatory activation of endothelial cells
and transporter changes that together result in NO synthesis dereg-
ulation. Furthermore, new actors, such as exosomes and miRs, appear
to contribute to the final manifestation of endothelial dysfunction.
Importantly, circulating miRs may represent potential biomarkers for
early GDM diagnosis [38], but additional studies are necessary to un-
derstand the impact of the growing number of GDM-associated miRs in
the vasculature pathological patterns of expression in pregnancy. Also,
new potential biomarkers have been reported such sex hormone
binding globulin, elevated triglycerides and reduction in HDL, in-
flammatory markers including TNF-α and IL-6, placental glucose
transporter and epigenetic modifications are under investigation [41].
Nevertheless, several issues related to reproducibility and selectively
need to be resolved before its clinical implementation.
3. Hypertensive disorders during pregnancy, preeclampsia and
eclampsia
3.1. Preeclampsia and eclampsia overview
The normal fetal development depends on maternal hemodynamic
and cardiovascular changes to comply with the increasing demand of
oxygen and nutrients [42]. A significant increase in the maternal blood
volume, is accompanied by a larger cardiac output, and vasodilation
that generates a decrease in the vascular resistance and subsequently in
the blood pressure [42]. Alterations in these adaptive changes may
develop pregnancy hypertensive disorders that affect 5% to 8% of ge-
stations. These pathologic conditions include chronic hypertension and
four pregnancy associated disorders: preeclampsia, eclampsia, super-
imposed preeclampsia and gestational hypertension [43]. These dis-
orders share the presence of hypertension but correspond to different
pathological entities [43]. Gestational hypertension is the evidence of
elevated blood pressure during pregnancy with no evidence of other
disorders and can be transient or represent the first sign of chronic
hypertension [44,45]. Preeclampsia is also characterized by proteinuria
and edema, while eclampsia is defined as preeclampsia in which cere-
bral involvement leads to the development of seizures in the patients.
Superimposed preeclampsia corresponds to the presence of pre-
eclampsia in patients with previous chronic hypertension [43–45].
Preeclampsia and eclampsia affect more than half a million of
women every year. Preeclampsia and eclampsia are responsible of 15%
of maternal deaths [46], significantly increase the risk of malformations
[44], reduce birth weight [45], and are the leading causes of indicated
preterm delivery [43]. Despite the normalization of the maternal vas-
cular disturbances after birth, formerly preeclamptic women have an
increased risk of cardiovascular and kidney disease later in life [47,48].
Eclampsia constitutes a severe form of preeclampsia, that can affect up
to 3% of women with preeclampsia, but can also develop in women
without obvious signs of preeclampsia [49]. The etiology of pre-
eclampsia has been proposed to be multifactorial, with a demonstrated
racial predisposition [50]. The genetic component in pregnancy-related
hypertensive disorders is supported by the fact that first degree re-
latives have a fourfold higher predisposition than the general popula-
tion [51]. A study in twins showed that in dizygotic twins, preeclampsia
was concordant in 2 out of 61 cases, but in monozygotic twins, it was
concordant in 8 out of 56 cases [52]. It was proposed then that 35% of
the variance in the risk of preeclampsia is due to a maternal genetic
C. Echeverria, et al. BBA - Molecular Basis of Disease 1866 (2020) 165414
4
effect and that 20% is due to fetal genetics [53].
3.2. Etiology of preeclampsia and eclampsia: a placental disorder of
immunological causes
Altered implantation of placenta has been traditionally accepted as
the primary event responsible for the histological abnormalities ob-
served in preeclampsia [7]. During normal placentation, cytotropho-
blasts are attached to the basement membrane that surrounds the
stromal core of chorionic villi [7]. Some of these cells fuse, forming
syncytial trophoblasts that cover the villus and transport nutrients be-
tween fetal and maternal blood. At specific locations, the cytotropho-
blasts break through the syncytium and form multilayered columns of
cells that invade the uterus [54]. These invasive extravillous cyto-
trophoblasts infiltrate the spiral arteries of the endometrium and re-
place the maternal endothelium in the arteries of the endometrium and
part of the myometrium and remodel the tunica media (the muscular-
elastic layer) of these arteries, consequently increasing the width and
decreasing the resistance of the spiral arteries, increasing the blood flow
according to fetal demand [55]. With the infiltration of cytotropho-
blasts, endothelial cells undergo apoptosis at the time that cyto-
trophoblasts adopt an endothelial phenotype in the spiral arteries [56].
It is largely accepted that preeclampsia is associated with the
shallow infiltration of cytotrophoblast cells, which lead to a narrowing
of arterioles and decreased blood flow; the consequent lack of nutrients
might be the main cause of the growth alterations observed in hy-
pertension-preeclampsia pregnancies [57]. Early histological studies
demonstrated the presence of morphological differences in the spiral
arteries of the placenta in patients with preeclampsia, and the diseased
group showed a lack of the arteries with increased diameter compared
to controls [58]. It was then suggested that the hypertension observed
in preeclampsia corresponds to a compensatory mechanism that pro-
vides adequate blood supply to the developing fetus. However, later
findings supported a two-stage model: In stage 1, placental ischemia is
generated by the impaired development of the spiral arteries, and in
stage 2, the ischemic placenta releases antiangiogenic factors into the
maternal circulation, causing generalized endothelial damage [59].
Because preeclampsia occurs mainly in first pregnancies and this
rate is lower in first pregnancies following a miscarriage, im-
munological causes and adaptation have been invoked as mechanisms
of preeclampsia [60]. Furthermore, an immunological adaptation to the
paternal genetic component has been proposed, since the preeclampsia
rate is higher in multiparous women with multiple partners than in
single-partner multiparous women [61,62]. Infectious diseases also
increase the risk of preeclampsia [63]. Researchers have proposed that
the Th2/Th1 switch together with high levels of inflammatory cyto-
kines such as TNF-α and IFN-γ and increased oxidative stress can lead to
an increase in the levels of FLT1, a known factor in the development of
preeclampsia [64]. These findings led to the proposal of a three-stage
model of development of preeclampsia, the currently most-accepted
model (Fig. 2). The first stage occurs during the very early stages of
development, during which a failed immunological tolerance to the
embryo occurs (the first stage). This impedes normal infiltration and
remodeling of the spiral arteries in the placenta (the second stage),
thereby generating placental ischemia with the release of anti-
angiogenic factors that have detrimental consequences for the maternal
endothelial functions (the third stage) (Fig. 2).
3.3. Cell interactions in the placental development as cause of preeclampsia
During the infiltration of cytotrophoblasts into the spiral arteries of
the uterus, the fetal cells undergo differentiation. The cells express
MMP9 to facilitate cell migration and express HLA-G, a specific tro-
phoblastic form of HLA-I, to prevent rejection by the maternal immune
system [65]. The cells exhibit decreased expression of α6β4 integrin
(laminin 332 receptor) and increased expression of integrin α5β1
(fibronectin receptor) and α1β1 (collagen IV receptor). The expression
of integrins αVβ3 (vitronectin receptor) and α1β1 (collagen and la-
minin receptors) as well as a reduction in the expression of E-cadherin
play key roles in cytotrophoblast invasion (Fig. 2) [66]. Cytotropho-
blasts express a normal endothelial cell cadherin pattern when they are
fully localized in the intima of the blood vessels [67] In conclusion, as
cytotrophoblasts differentiate, they downregulate adhesion receptors
that are characteristic of epithelial cells (integrin α6β4 and E-cadherin)
and upregulate receptors that are expressed by endothelial cells (α1β1,
αVβ3, VE-cadherin) (Fig. 2) [68].
The abovementioned changes are needed for normal placental de-
velopment. It has been demonstrated that cytotrophoblasts in pre-
eclampsia patients have important differences from those in control
patients. Cytotrophoblast cells of preeclampsia patients show lower α5
integrin and MMP9 expression than control patients, but no difference
is seen for α1 integrin [69]. Using immunohistochemical analyses of
biopsies of patients with preeclampsia, it was also demonstrated that
cytotrophoblasts exhibit downregulated α6β4 integrin compared to
that seen in normal development and do not express α1β1 integrin,
which is usually upregulated in these cells [70]. Furthermore, cyto-
trophoblasts in preeclampsia patients fail to upregulate the extra-
cellular matrix proteins receptors αVβ6 and αVβ3 integrin, suggesting a
decreased interaction with their extracellular matrix. In the same way,
these cells fail in the regulation of VE-cadherin and the leukocyte ad-
hesion molecule receptors αVβ6 and αVβ3 integrin, suggesting a de-
creased interaction with their extracellular matrix. In the same way,
these cells fail in the regulation of VE-cadherin and the leukocyte ad-
hesion molecule receptors integrin α4β1 and α4β7. These observations
demonstrate that the cells fail to develop the mechanisms for inter-
cellular adhesion that are critical for the appropriate function of blood
vessels [71].
3.4. Endothelial alterations in eclampsia: a consequence of decreased
placental perfusion
Placental hypoperfusion is accepted as the ultimate cause of en-
dothelial dysfunction. The hypoperfusion of placenta is due to the
narrow spiral arteries caused by a shallow infiltration of trophoblasts. A
major evidence of the effects of altered placental perfusion on maternal
hypertension has been provided by animal models of reduced uterine
perfusion pressure (RUPP) [72,73]. Despite the limitations induced by
these mechanisms that usually include aortic constriction, different
models of RUPP in mammals have demonstrated that the reduction in
blood supply in the uterus generates an increase in the maternal blood
pressure [74–76], and some of the effects revers after the normal blood
supply in the uterus is restored [72]. It has been proposed then that
under lack of oxygenation, placental cells release factors that affect the
endothelial function in the whole maternal circulation [72].
In preeclampsia, perfusion is decreased in all maternal organs,
secondarily to a generalized vasospasm generated by an increased
sensitivity of the vasculature to vasopressors [77], which has been
demonstrated to persist after delivery [5]. The maternal endothelial
dysfunction in preeclampsia generates increased systemic resistance,
thereby reducing the perfusion of all organs [8]. In order to evaluate if
these alterations are due to endothelial function, studies have measured
the effects of endothelium-dependent mechanisms of vasodilation such
as flow-mediated vasodilation, or acetylcholine-induced vasodilation.
These mechanisms are usually compared with the effects of smooth
muscle vasodilators such as nitroglycerin that acts preferentially in
venous smooth muscle, or sodium nitroprusside which preferentially
acts in arterial smooth muscle. Through these methods it has been
demonstrated that the endothelium-mediated vasodilation is altered in
preeclamptic women [78]. In vivo studies have demonstrated that in
large arteries, preeclamptic women experience a lower flow-mediated
(endothelium-dependent) vasodilation compared with non-pre-
eclamptic women, as measured by Doppler flow velocity pattern in
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brachial artery [79]. Interestingly, the microvasculature of women with
preeclampsia have a higher response to endothelium-dependent vaso-
dilation (acetylcholine) than non-preeclamptic women during preg-
nancy [80,81]. But there are no differences in the microvascular re-
sponse to endothelium-independent vasodilators (sodium
nitroprusside), demonstrating that the microvascular changes during
preeclampsia have an endothelial origin [80,81]. These contradictory
results in response to endothelium-mediated vasodilators in pre-
eclamptic women (lower vasodilation in large arteries and increased
vasodilation in microvasculature) should not be considered as com-
pensatory effect to maintain blood pressure, since microvasculature has
no capacity of overcoming changes in large vessels; indeed, the vaso-
dilation of large arteries and microvasculature do not correlate in
physiological or pathological conditions, and is accepted that respond
to different mechanisms [82]. The lower flow-mediated vasodilation
observed in large arteries, and increased acetylcholine induced vaso-
dilation of microvasculature in preeclamptic women, have shown to
persist after delivery, suggesting that these alterations are associated to
endothelial changes that persist in absence of placental factors [80,83].
Interestingly, the administration of ascorbic acid (inhibitor of oxidative
stress) increases the flow mediated vasodilation in large arteries of
former preeclamptic women but not in controls, demonstrating the role
of oxidative stress in mediating the endothelial dysfunction in pre-
eclampsia [83,84]. This association between oxidative stress and pre-
eclampsia has recently been shown to increase plasma biomarkers of
inflammation and oxidative stress such as 8-isoprostane, C-reactive
protein, IL-1β, IL-6 and IL-10, in preeclamptic women during pregnancy
[85].
Despite this progress, the molecular mechanisms that underlie these
functional alterations remain unclear. Many factors have been studied
in the search for soluble factors that could explain the endothelial al-
teration in pre-eclampsia. To date, factors that have shown a higher
association with the disease include the antiangiogenic soluble fms-like
protein kinase-1 (sFLT-1) and the proangiogenic placental growth
factor (PlGF) [86,87]. Gene expression analysis has demonstrated that
sFLT-1 is upregulated while free VEGF and free PlGF are reduced in the
placenta of preeclampsia patients [88]. In the same study, Maynard
et al. demonstrated that this elevation in sFLT-1 levels decreases the
angiogenesis induced by VEGF and PlGF as well as the vasodilation
produced by these two factors, thereby causing proteinuria and glo-
merular endotheliosis. Subsequent clinical studies have demonstrated
that pregnancies with poorer outcomes are associated with higher
serum levels of sFLT-1 and lower levels of PLGF [89,90]. A recent study
in 1055 women proposed a FLT-1/PlGF ratio of 38 as a cut-off in
pregnancy monitoring for predicting preeclampsia and found mean
levels of sFLT-1 of 4380 pg/mL in preeclampsia compared to 1643 pg/
mL in controls; for PlGF, the corresponding values were 90 mg/mL in
preeclampsia and 142 in control women [91]. An sFLT-1/PlGF ratio of
38 showed a 98.9% negative predictive value, 88.2% sensitivity, and
80% specificity. Commercial automated systems have been recently
released to measure the FLT-1/PlGF ratio for research and diagnostic
purposes [92].
3.5. Molecular effects on maternal endothelium
The elevated concentration of sFLT-1 and lower concentration of
PlGF in preeclampsia suggests that these molecules play a role in the
pathogenesis of pregnancy hypertension diseases rather than act as
simple markers of dysfunction. Placental growth factor was first de-
scribed in 1991 by Maglione et al. as a 149-amino acid protein sharing
53% homology with VEGF [93]. The secretion of PlGF and VEGF is
induced by the activation of HIF-a after exposure to hypoxia [94]. Si-
milar to VEGF, PlGF exists as a homodimeric glycoprotein that can bind
heparin, depending on its alternative splicing [95]. PlGF binds VEGF
Fig. 2. Three-stage model of preeclampsia.
Stage 1, immunological disorders affect maternal tolerance to the embryo, affecting the cytotrophoblasts infiltration in the developing placenta. Stage 2, the lack of
immunological tolerance affects placentation. As a consequence, exists an inhibition of the cytotrophoblast invasion of spiral arteries in the endometrium. This is
observed by the inhibition of the down regulation of adhesion molecules as E-cadherin and integrin α6β4, and inhibiting the expression of proteins that allows
migration such as matrix metalloprotease-9 (MMP-9), human leukocyte antigen-G (HLA-G) and the integrins α5β3, α5β1 and α1β1; this failure also prevents the final
differentiation into endothelial cells of spiral arteries that express VE-cadherin, and integrins α4β1 and α4β7. Stage 3, the ischemic placenta responds with an
increased secretion of the antiangiogenic soluble receptor sFLT-1, and decreased secretion of the angiogenic factors vascular endothelial growth factor (VEGF) and
the placenta growth factor (PlGF), which generates endothelial alterations in tissues and organs.
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receptor FLT-1 (VEGFR1) with high affinity and binds to the soluble
form sFLT-1 but does not bind the most active receptor FLK1/KDR
(VEGFR2). FLT-1 is a transmembrane receptor with tyrosine-kinase
activity. The binding of PlGF to FLT-1 results in the transpho-
sphorylation of FLK1/KDR. This FLT1-mediated phosphorylation en-
hances the downstream effects of FLK1/KDR activation by VEGF, which
are produced by the activation of PLCγ [96], and PI3K/AKT [97]. The
soluble form sFLT-1 is the truncated form of FLT-1 and is obtained by
alternative splicing of the same mRNA such that it does not encode the
transmembrane region [98]. This protein is a powerful specific in-
hibitor of the effects of VEGF [98]. sFLT-1 has a higher affinity for
VEGF than PlGF and inhibits the angiogenic effects of VEGF and PlGF
[99]. Experimental studies have demonstrated that the serum of pre-
eclampsia patients has a lower potential for inducing angiogenesis than
that of normotensive patients and that this effect results from the ele-
vated concentration of sFLT-1 [88]. The same study also demonstrated
that the elevated levels of sFLT-1 can induce hypertension and glo-
merular endotheliosis in a murine model. The authors then suggested
that the presence of soluble FLT-1 is causative of hypertension, renal
failure and proteinuria in preeclampsia [88]. Subsequent clinical stu-
dies have shown a positive correlation between the concentration of
sFLT-1 and proteinuria and between sFLT-1 and cardiovascular risk,
affecting both men and women [100]. Using blocking antibodies, the
anti-angiogenic effect of sFLT-1 was demonstrated in the serum of pa-
tients, as was the effect of sFLT-1 in increasing the apoptotic rate in
endothelial cells, thereby generating renal damage [100]; in addition,
elevated levels of sFLT-1 and PlGF have been associated with pul-
monary hypertension in men and women [101]. The presence of sFLT-1
does not itself affect endothelial cell function but acts by inhibiting
VEGF and PlGF activity. It has also been demonstrated that sFLT-1 acts
synergistically with the inflammatory effects of TGF-α, perhaps in-
hibiting the VEGF activation of iNOS [97]. The inhibitory effect of
sFLT-1 also affects other functions of VEGF, such as leucocyte migration
[102]. Taking these findings together, it seems that sFLT-1 is capable of
altering endothelial function by blocking the effects of VEGF; together
with a decrease in the level of PlGF, this could explain the effects on
liver and kidney function that lead to proteinuria and edema. However,
there is no certainty of how these molecules could generate permanent
alterations in the affected women. In the murine model in which sFLT-1
is increased during gestation, blood pressure, vascular function and
FLT-1 levels return to normal postpartum; for this reason, it is thought
that more complex molecular interactions are responsible for the per-
manent changes and damage to vascular function that occur during
eclampsia [103]. In humans, it has been shown that sFLT-1 decreases
rapidly postpartum in late onset preeclampsia, reaching normal levels,
but remains elevated in early onset preeclampsia [87].
In conclusion, preeclampsia is currently explained in a three-stage
model, in which the role of the immune system is still not fully un-
derstood. The mechanisms that provoke a shallow infiltration of tro-
phoblasts and thus generating a poor remodeling of spiral arteries are
not currently known, but the subsequent decreased placental dysfunc-
tion and its association with a generalized hypertension is widely ac-
cepted. Despite many soluble factors have been associated with PE
development, only sFLT-1 and PlGF are currently accepted markers of
the disease.
4. Obesity and hyperlipidemia during pregnancy
4.1. Normal lipid changes in plasma maternal plasma during pregnancy
Obesity during pregnancy is a prevalent condition, and its incidence
is increasing in the USA, Europe, Asia, Latin America, and Africa [104].
Obesity represents a significant risk factor for the mother by increasing
the risk of developing gestational diabetes [105], gestational hy-
pertensive disease [106], preeclampsia [105], eclampsia, thromboem-
bolic events, and complications of anesthesia during obstetric inter-
ventions [107]. Furthermore, it represents a significant risk factor for
the fetus to develop severe congenital malformations, congenital heart
defects, orofacial cleft, and gastrointestinal malformations, among
many others [108] (Fig. 3).
During pregnancy, it is well-known that due to the effects of es-
trogen, progesterone, and human placental lactogen, plasma lipid levels
increase significantly [109], which is associated with hypertriglycer-
idemia-induced attenuated endothelium-dependent relaxation in
human subjects with normal plasma low-density lipoprotein (LDL)
cholesterol levels [110]. Two mechanisms have been proposed for the
changed lipid profile during pregnancy. One is the estrogen-induced
hepatic synthesis of very low-density lipoprotein (VLDL) triglycerides
[111]. The second mechanism proposed to explain the increased TG in
all circulating lipoproteins during gestation is the impaired removal of
lipoprotein TG by one or both of the lipolytic enzymes, lipoprotein li-
pase and hepatic lipase [112].
Human pregnancy is associated with severe physiological hyperli-
pidemia, even during normal human gestation. Plasma high-density
lipoprotein (HDL)- and LDL-cholesterol levels are increased by 50%,
while TG levels increase between 2- and 4-fold [109,113]. The normal
gestational increase in TG is associated with a change in the LDL profile
[114,115]. It has been observed that maternal lipoproteins and trigly-
ceride concentrations is increased over time from preconception to the
third trimester of pregnancy [116]. LDL particles are the second smal-
lest lipo-protein particles, and their principal role is to transport cho-
lesterol to cells, where delivery is facilitated via the LDL receptor.
Oxidized LDL (oxLDL) and dense LDL particles have a particularly cy-
totoxic effect on endothelial function [115,117]. Once oxidized, LDL is
believed to have enhanced atherogenic potential, promoting foam cell
formation and initiating endothelial dysfunction [118]. OxLDL is a li-
gand for lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)
and is increased in the circulation of women with preeclampsia
[115,119].
Sankaralingam et al. used plasma from women with preeclampsia to
Fig. 3. Effects of maternal obesity during pregnancy
Diagram summarizing the effects of maternal obesity during pregnancy. Obesity
represents a cardinal risk factor for both mother and child, which alter serum
lipid composition before and during gestation. This leads to childbearing in an
oxidative and pro-inflammatory environment, having a deleterious impact on
endothelial and vascular physiology for both, mother and child.
C. Echeverria, et al. BBA - Molecular Basis of Disease 1866 (2020) 165414
7
increase the NAD(P)H oxidase-mediated superoxide and peroxynitrite
production by means of LOX-1 activation in endothelial cells [120]. In
addition to oxLDL, other circulating factors that are increased in pre-
eclampsia are also able to activate LOX-1. These include anionic
phospholipids, apoptotic cells, activated platelets, and bacteria [120].
Thus, LOX-1 pathway emerges as a key factor participating in en-
dothelial dysfunction and cardiovascular diseases during pregnancy
(Fig. 4). The oxLDL increases heme oxygenase system-1 (HO-1) induc-
tion in response to ROS [121]. HO-1 is a powerful anti-inflammatory
and vasodilator agent that exerts a protective effect against a wide
variety of pathological conditions during pregnancy [122,123]. It has
been reported that HO-1 has been used in the treatment of cardiovas-
cular diseases and hypertension [124,125] (Fig. 4). Furthermore, stu-
dies performed in pregnant mice showed an important participation for
the heme oxygenases in the establishment and maintenance of preg-
nancy and adequate placental blood flow [126]. HO-1 pathway has a
direct effect inhibiting endothelin-1 production in cultured human
glomerular endothelial cells, suggesting that HO-1 could inhibit pla-
cental ischemia-mediated endothelin-1 production, playing an im-
portant role in blood pressure regulation during placental ischemia
[127]. Interestingly, nuclear factor erythroid 2-related factor (Nrf2) is a
transcription factor that binds sites in the human HO-1 gene [128].
Because Nfr2 is activated in response to oxLDL [129,130], it is possible
to propose that oxHDL controls HO-1 levels by means of Nfr2 activity.
Congruently, Chigusa et al. observed that high oxLDL circulating levels
induces HO-1 expression in woman with preeclampsia [131]. The
finding of high serum HO-1 levels in maternal and cord blood in pre-
eclampsia suggests that heme derived from free hemoglobin in plasma
may threaten vascular endothelial cell integrity via the oxidative
modification of LDL [132].
4.2. Blood lipid composition and endothelial dysfunction during pregnancy
Hyperlipidemia can compromise endothelial function, and this may
contribute to the development of atherosclerotic vascular disease
[133,134]. In complicated pregnancies, the mechanisms regulating
physiological hyperlipidemia may malfunction. Abnormal lipid profiles
and species may play a role in the promotion of the oxidative stress and
vascular dysfunction that occur in preeclampsia [135]. When LDL
particles are oxidized, they are readily taken up into macrophages via
the scavenger receptor, promoting foam cell formation and the devel-
opment of atherosclerotic lesions, thereby initiating vascular occlusion
and endothelial dysfunction [136]. In addition, increased levels of lipid
hydroperoxide in pregnancy have been associated with the develop-
ment of atherosclerosis and an increased risk of cardiovascular diseases
[137], especially in women with Type II diabetes [138]. Women with a
history of preeclampsia have significant differences in their lipid
parameters and exhibit an increased susceptibility to lipoprotein oxi-
dation when compared with women who had a normal pregnancy one
to three years after delivery [139]. Cekmen et al. found that abnormal
lipid metabolism and particularly high TG, LDL and lipid peroxide
concentrations and low HDL concentrations may contribute to the
promotion of oxidative stress and endothelial dysfunction in pre-
eclampsia [134]. Among those who develop preeclampsia, an addi-
tional change in the lipid metabolism is present since plasma TG levels
are further increased compared to women with normal pregnancies
[140]. These results are consistent with findings reported in studies of
other populations. Patients with preeclampsia had lower mean serum
HDL and higher mean TG concentrations than control groups in the
Finnish and Peruvian populations [141,142]. Hyperlipidemia with
oxidative stress resulting in lipid peroxidation may add to the promo-
tion of vascular dysfunction, leading to pregnancy-induced hyperten-
sion [143]. In the area of cardiovascular research, there is increasing
evidence that hyperlipidemia can cause endothelial dysfunction [144].
In recent years, the evaluation of lipid profiles during pregnancy have
been required for the early diagnosis of cardiovascular risk factors,
especially in high risk populations [145]. Elevated TG-rich lipoprotein
levels constitute a substantial cardiovascular risk factor and are perhaps
as important as cholesterol [146,147]. Hypertriglyceridemia is asso-
ciated with attenuated endothelium-dependent relaxation in human
subjects with normal plasma LDL-cholesterol levels [110]. Plasma HDL
concentrations increase at 10 weeks of gestation and reach a maximum
level with a 42% increased concentration at 20 weeks of gestation; le-
vels then decline to a plateau at only 7% above early pregnancy levels
by 30 weeks of gestation [110]. The postpartum decline in HDL con-
centration is delayed until approximately 10 weeks after delivery, and
pregnancy levels are eventually reached by 20 weeks after delivery
[148]. These researchers propose the existence of a new HDL in plasma
that improves the feto-placental circulation. The increased serum con-
centrations of TG, LDL-cholesterol, and VLDL-cholesterol did not lead to
endothelial dysfunction during pregnancy. In contrast, endothelial
function improved in the second and third trimesters of the pregnancy,
partly because of the increased concentration of HDL-cholesterol, which
may inhibit the oxidation of LDL and thus protect the endothelium
[149] (Fig. 4).
Interestingly, exposure of human umbilical vein endothelial cells
(HUVEC) to VLDL and oxidized-VLDL particles leads to a dose-depen-
dent decrease in the expression of endothelial NO synthase (eNOS) as
well as to differences in phosphorylation at key regulatory sites,
Ser1177 and Thr495. Moreover, nitrite-nitrate, ROS, and 3-nitrotyr-
osine accumulation showed a proportional increase that was consistent
with eNOS uncoupling. This imbalance in NO and ROS metabolism
promotes the modification of relevant proteins, including mitochon-
drial proteins that are involved in oxidative phosphorylation [150].
Thus, persistent stimulus of VLDL in an oxidative environment leads to
a decrease in mitochondrial respiration, endothelial cell dysfunction
and, eventually, cell death [150].
Among endothelial cell products, one class of molecules that has
been suggested to play a critical role in preeclampsia is the prostanoids
[151]. The major prostanoid produced by endothelial cells is prosta-
cyclin, a powerful cardioprotective hormone that is released by the
endothelium of all blood vessels. It has been observed that preeclamptic
Fig. 4. Hyperlipidemia during pregnancy.
Hyperlipidemia during pregnancies is associated with increases in LDL, TG and
HDL. ROS production induces oxLDL. Increased plasma levels of TG and oxLDL
are usually associated with endothelial dysfunction. HO-1 inhibits the oxidation
of LDL to form oxidized oxLDL. HDL can also inhibit endothelial dysfunction,
decreasing the risk of cardiovascular disease. LDL: Low density lipoprotein; TG:
Triglyceride; HDL: High density lipoprotein; oxLDL: Oxidized Low density li-
poprotein; HO-1: heme oxygenase system-1.
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women release less prostacyclin from endothelial cells. This effect is
associated with a 3-fold increase in the cellular TG content [152]. The
latter finding indicates that the lipoproteins in and lipid metabolic
properties of sera from preeclamptic women are different from those of
the sera of uncomplicated pregnancies [152]. Experiments performed in
human cultured endothelial cells suggest that elevated levels of free
fatty acids cause reduction in prostacyclin and NO production, which
could result in diminished relaxation capacity [111]. The inhibition
resulting from the secretion of prostacyclin might be associated with
the endothelial dysfunction reflected by an increase in plasma TG.
The endothelial dysfunction in preeclampsia might originate from
oxidative stress and dyslipidemia. Free radicals can be generated by
many enzymatic processes. These species are extremely reactive and
interact with polyunsaturated fatty acids to produce lipid peroxides
with a much longer half-life [153–155]. An association of dyslipidemia
and the lipid peroxidation product malondialdehyde (MDA) with se-
verity of pregnancy-induced hypertension has been documented. This
increase in MDA is strongly related to the lipid peroxidation caused by
oxidative stress and is expected to affect various tissues and organ
systems, including the vascular endothelium [154,156,157]. Estimation
of the serum lipid profile and MDA in pregnant women during antenatal
care can be useful in the early diagnosis of pregnancy-induced hy-
pertension and the prevention of obstetric complications [143]. Oxi-
dative stress is a major contributing factor to tissue injury, apoptosis
and aging. ROS are mainly created as byproducts of normal metabolic
functions such as breathing and mitochondrial energy generation.
Oxidative stress might mainly affect endothelial vessels and many tis-
sues and organs, both locally and systematically. During these pro-
cesses, other molecules that play a role in vasodilatation, such as nitric
oxide, are inhibited by high lipid peroxide concentrations [153,155].
Plasma lipid peroxide levels are also significantly elevated [158],
whereas Vitamin E and other plasma antioxidants are decreased in
preeclampsia [158–160]. Wakatsuki et al. showed that in post-
menopausal women, the administration of antioxidants reduces the
susceptibility of LDL to oxidative modification [161].
4.3. High fat intake leads to obesity and altered blood lipid composition
during pregnancy
Similarly, in a mouse model with obesity induced by a high-fat diet
(HFD) or a “Western-style diet” (high in calories and saturated fats), the
metabolic profiling of pregnant mouse plasma revealed significant
changes in the levels of multiple amino acid metabolites, thereby re-
vealing a significant increase in lysine catabolites and a significant
decrease in acetylated lysine, glycine, and several glycine metabolites;
this likely reflects an impaired utilization of carbohydrates, especially
when insulin resistance is present, thus promoting the oxidation of
amino acids as an alternative energy source as they enter the citric acid
cycle at different points [162]. Analogously, significant changes in the
levels of biochemicals involved in fatty acid metabolism in maternal
plasma were revealed. In particular, long-chain fatty acids, poly-
unsaturated fatty acids, and ω-6 fatty acids were significantly increased
in HFD dams. The increases in glycerophospholipids and sphingomyelin
species together with decreases in carnitine and its metabolic precursor,
deoxycarnitine, that were detected in the plasma of the obese dams
suggest that significant alterations in β-oxidation had occurred [162].
Analogously, a recent study found that maternal obesity (pregestational
body mass index (BMI) > 30) is accompanied by a change in serum
lipid composition [163]. Obese patients exhibit a characteristic pattern
involving significant increases in concentration of several low-density
lipoproteins (LDL) subclasses (e.g., the concentration of medium, large,
and very large LDL particles; total and free cholesterol and cholesterol
esters in very large VLDL particles; the concentration of chylomicrons;
and the concentration of phospholipids in VLDL particles) and sig-
nificant decreases in the concentration of free cholesterol in inter-
mediate-density lipoproteins and several high-density lipoproteins
subclasses (i.e., total cholesterol and cholesterol esters in high-density
lipoprotein particles, as well as polyunsaturated fatty acids) [163].
4.4. Obesity during pregnancy leads to redox imbalance and inflammation
Recent observations indicate that maternal obesity has a substantial
impact on the inflammatory state of the mother at both the placental
and systemic levels (Fig. 3). Evidence from in vitro studies reveals that
treatment of HUVEC with palmitate (a long-chain fatty acid) increases
intracellular ROS production and decreases cell proliferation [164].
Moreover, treatment of HUVEC with trans fatty acids (which are present
in fast foods, bakery products, packaged snacks, and margarines [165]),
results in an increase in the expression of proteins that are involved in
pathways related to the biosynthesis of amino acids, the synthesis and
degradation of ketone bodies, cysteine and methionine metabolism,
fatty acid degradation, and several others [166]. This shift in lipid
composition in sera obtained from obese female subjects is accom-
panied by a significant increase in the levels of inflammation-related
proteins [167]. In particular, C-reactive protein and GlycA (a complex
NMR signal reflecting the abundance of N-acetyl sugar groups on gly-
coproteins) were found to be significantly increased in obese pregnant
women (pregestational BMI > 30) [163,168]. In addition, IL-6, C-re-
active protein, CCL22, IL-8, and CCL4 as well as the frequency of cir-
culating CD4+ T-cells and their response to stimulation were found to
be increased in pregravid obese mothers [169]. Similarly, visceral
adipose tissue-resident and recruited macrophage subsets show upre-
gulated CD11c, CD163, and CD206 expression in obese pregnant
women (pregestational BMI > 30) [170]. Moreover, uterine NK activity
is imbalanced in decidua obtained from obese pregnant women (preg-
estational BMI > 30). Specifically, cell degranulation is significantly
increased, NK-receptor phenotype is modified, and TNFα production is
potentiated [171]. This effect has been identified not only in human
patients but also in animal subjects. Observations in pregnant Japanese
macaques show that maternal obesity (induced by an HFD) stimulates a
significant increase in pro-inflammatory mediators (i.e., IL-12, IL-1β,
MIP-1a, GM-CSF, ICAM-1, IFN-γ, and TNF-α) [172]. Observations in
obese pregnant swines show that increased levels of fatty acid meta-
bolites in obese pregnant subjects stimulate placental lipotoxicity, in-
flammation, and oxidative stress [173]. Proteins related to lipid meta-
bolic processes (e.g., fatty acid synthase, lipoprotein lipase, and Fatty
Acid Transport Protein 2) and immune and inflammatory responses
(e.g., TLR4, IL-6, and IL-1β) were significantly upregulated in the pla-
centa of obese sows. Areas of the villous stroma with increased fatty
acid deposits were significantly enriched in lipid regulation-related
proteins and accumulated macrophages. Moreover, proteomic analyses
corroborated by RT-PCR and Western blot analyses revealed that pro-
inflammatory cytokines IL-6, IL-8, IL-18, and TNFα; receptors TLR2 and
TLR4; and inflammation signaling pathway proteins JNK and NF-κB
exhibited upregulated mRNA and protein expressions in the placenta in
the obese group. Interestingly, placental samples exhibited a reduced
antioxidant capacity, as measured by a total antioxidant capacity ana-
lysis [173].
As mentioned above, HFD and inflammation affect redox home-
ostasis (Fig. 3). The assessment of antioxidant status reveals that pla-
cental homogenates from obese pregnant women (pregestational
BMI > 30) have decreased antioxidant activity, as measured by catalase
activity. Moreover, and consistent with results obtained by Magnifico
et al. [150], protein carbonyl formation is significantly increased in
mitochondrial extracts obtained from obese-women placenta (an in-
direct indicator of increased ROS levels). Nitric oxide generation and
mitochondrial nitrative stress are also significantly increased in the
placenta of obese pregnant women (pregestational BMI > 30) [174].
Furthermore, maternal obesity has profound effects on antioxidant
metabolizing enzymes. In a rat model, glutathione peroxidase was
significantly increased, while glutathione reductase activity was sig-
nificantly reduced, when compared to control rats [175].
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4.5. Obesity during pregnancy and its consequences to vascular function
This impaired inflammatory and oxidative environment result in
endothelial dysfunction and improper vascular function (Fig. 3). As
observed in animal studies, maternal obesity induces a significant de-
crease in total maternal-side placental blood flow and in-flow velocity
of blood flow to the placenta, while transit time through the spiral
arteries is significantly increased with respect to lean control subjects
[172]. Similarly, exposure to an HFD determines a decrease in placental
microvessel density, being lower in the placenta associated with male
offspring than in that associated with female placenta throughout ge-
station [162]. Moreover, an increase in dietary fat may lead to path-
ways inhibiting angiogenesis and result in endothelial dysfunction by
abolishing vascular endothelial growth factor or insulin-stimulated
endothelial nitric oxide synthase activation and subsequent nitric oxide
production from endothelial cells [176]. Interestingly, some of these
parameters may be restored to levels close to control subjects only by
reversing the HFD to a control diet just prior to the pregnancy [172].
In conclusion, evidence from studies performed in vitro, in vivo, and
in human subjects, is univocal pointing obesity as a threat to pregnancy.
Causal chain may be originated by an imbalanced diet leading to obe-
sity, in turn leading to inflammation and oxidative stress, which re-
presents a dangerous baseline for pregnancy, increasing the risk of
vascular endothelial complications and impaired nutrient exchange.
Thus, to reduce the burden of these disorders, public policies regarding
obesity and healthy lifestyles during childbearing ages should be
strengthened.
5. Conclusions
During pregnancy, a number of changes take place in response to
the high metabolic demand from organ and tissues. For this reason,
pregnancy is a vulnerable condition in which to acquire and develop
pathophysiological disorders. In this context, the pathological condi-
tions described in this review cause severe detrimental effects in the
vascular relationship among the mother, placenta and fetus, generating
changes in the endothelium at the cellular and molecular levels.
Unfortunately, despite basic and clinical research, advances in under-
standing and effective treatments for pregnancy disorders compro-
mising endothelium physiology are far from satisfactory. For this
reason, it is necessary further basic and clinical research to reach a good
understanding in the role played by endothelial cells during pregnancy
disorders and to develop more effective therapies.
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